Current Report Filing (8-k)
November 04 2022 - 6:07AM
Edgar (US Regulatory)
0000316253
false
0000316253
2022-10-20
2022-10-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): November 3, 2022 (October 20, 2022)
Enzo
Biochem, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
New
York
(State
or Other Jurisdiction of Incorporation)
001-09974 |
|
13-2866202 |
(Commission
File Number) |
|
(IRS
Employer Identification No.) |
|
|
|
81
Executive Blvd. Suite 3 |
|
|
Farmingdale, New York |
|
11735 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
(212)
583-0100
(Registrant’s
Telephone Number, Including Area Code)
N/A
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class |
|
Trading
Symbol |
|
Name
of Each Exchange on Which Registered |
Common
Stock, $0.01 par value |
|
ENZ |
|
The
New York Stock Exchange |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-1 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
October 20, 2022, Enzo Biochem, Inc. (the “Company”) entered into (i) a first amended and restated employment agreement with
Kara Cannon, its Chief Operating Officer (the “COO A&R Agreement”), and (ii) a second amended and restated employment
agreement with Hamid Erfanian, its Chief Executive Officer (the “CEO Second A&R Agreement,” and together with the COO
A&R Agreement, the “Employment A&R Agreements”).
Pursuant
to the amended terms of the Employment A&R Agreements, each of Ms. Cannon and Mr. Erfanian is now eligible to receive a transaction
bonus in the event that there is a sale of an operating subsidiary.
The
foregoing descriptions of the Employment A&R Agreements are not complete and are qualified in their entirety by reference to full
text of the COO A&R Agreement and the Employment A&R Agreements, copies of which are attached hereto as Exhibit 10.1 and Exhibit
10.2, respectively, and are incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
ENZO
BIOCHEM, INC. |
|
|
|
Date:
November 3, 2022 |
By: |
/s/
Hamid Erfanian |
|
|
Hamid
Erfanian |
|
|
Chief
Executive Officer |
2
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Jul 2023 to Jul 2024